Treatment for VEXAS syndrome. It is steroid responsive. Avoid IL-1 inhibitors severe skin reactions at injection site, bone marrow transplant may be curative @RheumNow #ACR21 Session6S410 L Wilson, DO Cordona https://t.co/eQ1KVDiKKV

JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease Dr. Bella Mehta ( @bella_mehta) shares abstract findings from #ACR21. https://t.co/4FyXX5JIyZ https://t.co/YAJOwvLbLS

• https://bit.ly/3bUKBfY

#ACR21 L20- Anti-IFN Ab Emapalumab for MAS/sJIA ⭐️⬆️IFN in models of HLH/MAS, neutralization may be helpful ⭐️Pilot study in 14 pts w inadequate response to high-dose IV GC ⭐️Ok to continue IL1i ▶️13/14 pts remission ▶️ SAEs: 1 CMV reactivation https://t.co/cuM9LcEr4u @RheumNow https://t.co/USYGNtq4eC

• https://bit.ly/3mUsMUp

Having an auto-inflammatory disease specialist available via telemedicine/video for near home providers for pts. Well received by primary care, pediatricians and internal medicine physicians. Will improve the care of auto inflammatory patients! #ACR21 @rheumnow #abt1062

#ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated MAS, Emapalumab (anti-IFNγ) induced remission in all pts with median 25 days, neutralised CXCL9 and allowed rapid steroid reduction @RheumNow #ACRBest https://t.co/7tnaS5tPJ0 https://t.co/G1IoFxLQoX

• Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activ…